Evolution dans la prise en charge de l'adenocarcinome du pancreas localise estime resecable.

VAN DAELE, Daniel; Puleo, F.; Dumont, R.; POLUS, Marc; Loly, Catherine; Martinive, Philippe; Meunier, Paul; Collignon, J.; Hendlisz, A.; Marechal, R.; Louis, Edouard; Van Laethem, J.-L.

Request a copy

Article (Scientific journals)

Evolution dans la prise en charge de l'adenocarcinome du pancreas localise estime resecable.

VAN DAELE, Daniel; Puleo, F.; Dumont, R. et al.

2015 • In Revue Médicale Suisse, 11 (483), p. 1543-8

Peer Reviewed verified by ORBi

Permalink
https://hdl.handle.net/2268/194431

PubMed
26502580

Files (1)Send to Details Statistics Bibliography Similar publications

Files

Full Text

evolution dans la prisse.pdf

Publisher postprint (566.42 kB)

Request a copy

All documents in ORBi are protected by a user license.

Send to

RIS BibTex APA Chicago Permalink X Linkedin

Details

Keywords :

Carcinoma, Pancreatic Ductal/therapy; Humans; Pancreatic Neoplasms/therapy

Abstract :

[en] Pancreatic ductal adenocarcinoma is characterized by a high rate of early metastatic relapse. Surgical resection is still recognized as the cornerstone upfront therapy. However, reported 5 years survival rates are inferior to 20-25% even when surgery is followed by chemotherapy. Margins involvement on the surgical specimen (50 to 85%) and lymph node involvement (around 70%) both strongly impact survival. Median survivals are close to those of locally advanced diseases treated by chemotherapy or chemoradiotherapy, 15 to 16 months. This review focuses on adverse prognostic factors, post-operative outcomes and their impact on multimodality therapy completion rates and survivals in patients undergoing upfront surgery. Current data and emerging results from neoadjuvant series could lead to a change in the therapeutic strategy.

Disciplines :

Oncology

Author, co-author :

VAN DAELE, Daniel ; Centre Hospitalier Universitaire de Liège - CHU > Gastro-Entérologie-Hépatologie

Puleo, F.

Dumont, R.

POLUS, Marc ; Centre Hospitalier Universitaire de Liège - CHU > Service de gastroentérologie, hépatologie, onco. digestive

Loly, Catherine

Martinive, Philippe ; Université de Liège > Département des sciences biomédicales et précliniques > Département des sciences biomédicales et précliniques

Meunier, Paul ; Université de Liège > Département des sciences cliniques > Département des sciences cliniques

Collignon, J.

Hendlisz, A.

Marechal, R.

Louis, Edouard ; Université de Liège > Département des sciences cliniques > Hépato-gastroentérologie

Van Laethem, J.-L.

Language :

French

Title :

Evolution dans la prise en charge de l'adenocarcinome du pancreas localise estime resecable.

Alternative titles :

[en] Evolution in the therapeutic strategy of localized resectable pancreatic ductal adenocarcinoma

Publication date :

2015

Journal title :

Revue Médicale Suisse

ISSN :

1660-9379

Publisher :

Medecine et Hygiène, Switzerland

Volume :

Issue :

483

Pages :

1543-8

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 08 March 2016

Statistics

Number of views

75 (9 by ULiège)

Number of downloads

5 (1 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenAlex citations

Bibliography

GLOBOCAN 2012 v2.0. Cancer incidence and mortality worldwide. International Agency for Research on Cancer, Lyon, France. http://globocan.iarc.fr/fact sheet. asp
Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014; 64:9-29.
Mayer RJ, Venook AP, Diller H, et al. Progress against GI cancer during the American Society of Clinical Oncology's first 50 years. J Clin Oncology 2014; 32:1521-30.
Ryan DP, Hong TS, Bardeesy N. Pancreatic adenocarcinoma. N Engl J Med 2014; 371:1039-49.
Howard TJ, Krug JE, Zyromshi NJ, et al. A marginnegative R0 resection accomplished with minimal postoperative complications is the surgeon's contribution to long-term survival in pancreatic cancer. J Gastrointest Surg 2006; 10:1338-45.
Schwarz L, Sa Cunha A. Les critères de résécabilité des adénocarcinomes pancréatiques en 2014. Hepato-Gastro et Oncologie Digestive 2014; 21:727-36.
Katz MH, Marsh R, Herman JM, et al. Borderline resectable pancreatic cancer: Need for standardization and methods for optimal clinical trial design. Ann Surg Oncol 2013; 20:2787-95.
Yamada S, Fujii T, Sugimoto H, et al. Aggressive surgery for borderline resectable pancreatic cancer: Evaluation of National Comprehensive Cancer Network guidelines. Pancreas 2013; 42:1004-10.
Tran Cao HS, Balachandran A, Wang H, et al. Radiographic tumor-vein interface as a predictor of intraoperative, pathologic, and oncologic outcomes in resectable and borderline resectable pancreatic cancer. J Gastrointest Surg 2014; 18:269-78.
Lee ES, Lee JM. Imaging diagnosis of pancreatic cancer: A state-of-the-art review. World J Gastroenterol 2014; 20:7864-77.
Verbeke CS, Menon KV. Redefining resection margin status in pancreatic cancer. HPB 2009; 11:282-9.
Campbell F, Bennett M, Foulis AJ. Minimum dataset for histopathological reporting of pancreatic, ampulla of vater and bile duct carcinoma. London: Royal College of Pathologists. www.rcpath.org
Ouaissi M, Hubert C, Verhelst R, et al. Vascular reconstruction during pancreatoduodenectomy for ductal adenocarcinoma of the pancreas improves resectability but does not achieve cure. World J Surg 2010; 34:2648-61.
Yu XZ, Li J, Fu DL, et al. Benefit from synchronous portal-superior mesenteric vein resection during pancreaticoduodenectomy for cancer: A meta-analysis. EJSO 2014; 40:371-8.
Delpero JR, Bachellier P, Regenet N, et al. Pancreaticoduodenectomy for pancreatic ductal adenocarcinoma: A French multicentre prospective evaluation of resection margins in 150 evaluable specimens. HPB 2014; 16:20-33.
Neoptolemos JP, Stocken DD, Friess H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 2004; 350:1200-10.
Oettle H, Neuhaus P, Hochhaus A, et al. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: The CONKO-001 randomized trial. JAMA 2013; 310: 1473-81.
Regine WF, Winter KA, Abrams R, et al. Fluorouracil-based chemoradiation with either gemcitabine or fluorouracil chemotherapy after resection of pancreatic adenocarcinoma: 5-year analysis of the U.S. Intergroup/RTOG 9704 phase III trial. Ann Surg Oncol 2011; 18:1319-26.
Van den Broeck A, Ectors N, Van Steenbergen W, et al. Patterns of recurrence after curative resection of pancreatic ductal adenocarcinoma. Eur J Surg Oncol 2009; 35:600-4.
Cameron JL, Riall TS, Coleman J, et al. One thousand consecutive pancreaticoduodenectomies. Ann Surg 2006; 244:10-5.
Sohal DP , Walsh RM , Ramanathan RK, et al. Pancreatic adenocarcinoma: Treating a systemic disease with systemic therapy. J Natl Cancer Inst 2014; 106: dju011.
Hartwig W, Hackert T, Hinz U, et al. Pancreatic cancer surgery in the new millennium. Better prediction of outcome. Ann Surg 2011; 254:311-9.
Winter JM, Brennan MF, Tang LH, et al. Survival after resection of pancreatic adenocarcinoma: Results from a single institution over three decades. Ann Surg Oncol 2012; 19:169-75.
Lewis R, Drebin JA, Callery MP, et al. A contemporary analysis of survival for resected pancreatic ductal adenocarcinoma. HPB 2013; 15:49-60.
Halloran CM, Ghaneh P, Bosonnet L, et al. Complications of pancreatic cancer resection. Dig Surg 2002; 19:138-46.
Aloia TA, Lee JE, Vauthey JN, et al. Delayed recovery after pancreaticoduodenectomy: A major factor impairing the delivery of adjuvant therapy. J Am Coll Surg 2007; 204:347-55.
Valle JW, Palmer D, Jackson R, et al. Optimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas: Ongoing lessons from the ESPAC-3 study. J Clin Oncol 2014; 32:504-12.
Chang DK, Johns AL, Merrett ND, et al. Margin clearance and outcome in resected pancreatic cancer. J Clin Oncol 2009; 27:2855-62.
Rau BM, Moritz K, Schuschan S, et al. R1 resection in pancreatic cancer has significant impact on longterm outcome in standardized pathology modified for routine use. Surgery 2012; 152(Suppl.):S103-11.
He J, Ahuja N, Makary MA, et al. 2564 resected periampullary adenocarcinomas at a single institution: Trends over three decades. HPB 2014; 16:83-90.
Hartwig W, Gluth A, Hinz U, et al. Total pancreatectomy for primary pancreatic neoplasm. Renaissance of an unpopular operation. Ann Surg 2015; 261:537-46.
Hammel P, Huguet F, Van Laethem JL, et al. Comparison of chemo-radiotherapy (CRT) and chemotherapy (CT) in patients with locally advanced pancreatic cancer (LAPC) controlled after 4 months of gemcitabine with or without erlotinib: Final results of the international phase III LAP 07 study. J Clin Oncol 2013; 31:(abstr LBA 4003).
Varadhachary GR, Wolff RA, Crane CH, et al. Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head. J Clin Oncol 2008; 26: 3487-95.
Evans DB, Varadhachary GR, Crane CH, et al. Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. J Clin Oncol 2008; 26:3496-502.
Katz MH, Pisters PW, Evans DB, et al. Borderline pancreatic cancer: The importance of this emerging stage of disease. J Am Coll Surg 2008; 206:833-46 ; discussion 846-8.
Lim KH, Chung E, Khan A, et al. Neoadjuvant therapy of pancreatic cancer: The emerging paradigm ? The Oncologist 2012; 17:192-200.
Gillen S, Schuster T, Meyer Zum Bischenfelde C, et al. Preoperative/neoadjuvant therapy in pancreatic cancer: A systematic review and meta-analysis of response and resection percentages. PLoS Med 2010; 7: e1000267.
Roland CL, Yang AD, Katz MH, et al. Neoadjuvant therapy is associated with a reduced lymph node ratio in patients with potentially resectable pancreatic cancer. Ann Surg Oncol 2015; 22:1168-75.
Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 2013; 369:1691-703.
Conroy T, Desseigne F, Ychou M, et al. Groupe tumeurs digestives of unicancer, PRODIGE Intergroup. folfirinox versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011; 364:1817-25.
Mukherjee S, Hurt CN, Bridgewater J, et al. Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): A multicentre, randomized, phase 2 trial. Lancet Oncol 2013; 14:317-26.
Heestand GM, Murphy JD, Lowy AM. Approach to patients with pancreatic cancer without detectable metastases. J Clin Oncol 2015; 33:1770-8.
NEOPAC Trial. Adjuvant versus neoadjuvant plus adjuvant chemotherapy in resectable pancreatic cancer. https://clinicaltrials.gov/ct2/show/NCT01314027
Tempero MA, Malafa MP, Behrman SW et al. Pancreatic adenocarcinoma, version 2.2014: Featured updates to the NCCN guidelines. JNCCN 2014; 12:1083-93.
Seufferlein T, Bachet JB, Van Cutsem E, et al. Pancreatic adenocarcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012; 23(Suppl. 7): vii33.
Katz MH, Shi Q, Ahmad S, et al. Preoperative mfolfirinox followed by chemoradiation for borderline resectable PDAC. Initial results from ALLIANCE Trial A021101. J Clin Oncol ASCO 2015, Abst LBA 4008.
Pietrasz D, Wagner M, Sa Cunha A, et al. Adénocarcinomes du pancréas borderline et localement avancés réséqués après chimiothérapie d'induction par folfirinox: résultats d'une étude multicentrique AGEO/FRENCH. Communications orales CO.101, JFHOD 2015.
Jones S, Zhang X, Parsons DW, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 2008; 321:1801-6.
Bachet JB, Maréchal R, Demetter P, et al. Contribution of CXCR4 and SMAD4 in predicting disease progression pattern and benefit from adjuvant chemotherapy in resected pancreatic adenocarcinoma. Ann Oncol 2012; 23:2327-35.
Bachet JB, Maréchal R, Demetter P, et al. S100A2 is a predictive biomarker of adjuvant therapy benefit in pancreatic adenocarcinoma. Eur J Cancer 2013; 49:2643-53.
Maréchal R, Bachet JB, Mackey JR, et al. Levels of gemcitabine transport and metabolism proteins predict survival times of patients treated with gemcitabine for pancreatic adenocarcinoma. Gastroenterology 2012; 143:664-74.
Iacobuzio-Donahue CA, Fu B, Yachida S, et al. DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. J Clin Oncol 2009; 27:1806-13.
Maréchal R, Bachet JB, Calomme A, et al. Sonic hedgehog and gli1 predict outcome in resected pancreatic adenocarcinoma. Clin Cancer Res 2015; 21:1215-24.